Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Mycronic receives order for two SLX systems

Mycronic AB (publ) has received an order for two SLX mask writers from an existing customer in the USA. The total order value is between USD 8 and 12 million. Delivery of the first SLX system is scheduled for the fourth quarter of 2021, while delivery of the second system is scheduled for the first half-year of 2022.The SLX laser mask writer was launched in October 2019 to meet rising demand for photomasks for the semiconductor industry, which is driven by long-term trends, and to meet the future need for replacement and modernization. Photomasks made by laser mask writers are very

DanCann Pharma A/S publishes Year-end report for 2020

COPENHAGEN, Denmark, 26 February 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) today releases its results for the period 1 January – 31 December 2020. The Year-end report is available as an attached document to this press release and on www.dancann.com.Fourth quarter 2021 (1 October – 31 December) · Net sales was KDKK 0 (0) · Operating profit (EBIT) was -2,721 (-493) · Result per share (DKK) was -0.07 (-460,000)* · Equity ratio was 0.89 (-0.42) Full year 2020 (1 January – 31 December) · Net sales was KDKK 0 (0) · Operating profit (EBIT)

Recurring revenue continues to grow while churn remains at 0%

Interim Report October 1st – December 31th, 2020   • Despite a quarter with lead times affected by the pandemic, the Annual Recurring Revenue(ARR) increased with +37% year-on-year, to 23,8 MSEK.• The transformation in 2020 came to full completion in the fourth quarter. On a full-year basisrecurring revenues accounted for 90% of total revenues.• Churn in Q4 remains at 0%.• On January 25th, Safeture carried out a directed share issue of 4,6 million shares worth 38,6MSEK in new cash.Summary of Interim Report The Group Full Year (2020-01-01 to 2020-12-31) · Net

Year-end Report January-December 2020

SECURED FINANCING OF KARLATORNETOctober–December 2020 · Order bookings amounted to SEK 4,852 million (2,969). · Income amounted to SEK 2,166 million (2,253). · Operating loss amounted to SEK 47 million (97). · Cash flow from operating activities amounted to SEK 204 million (83). · Loss for the period amounted to SEK 72 million (63). · On December 17, 2020, Serneke and Balder entered a share transfer agreement meaning that Balder acquires 50 percent of the shares of Karlatornet AB (“the Joint Venture”). The Joint Venture is a newly established company that has acquired

Number of shares and votes in Medivir

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during February 2021 as a result of the previously announced rights issue and over-allotment option and which in total resulted in an increase of 27,847,833 class B shares. Today, the last trading day of the month, there are in total 52,135,651 shares in Medivir, of which all are class B shares with in total 52,135,651 corresponding voting rights. For additional information, please contactYilmaz Mahshid, CEOTelephone: +46 8 5468 3100E-mail: yilmaz.

myFC Holding AB (publ) year-end report January – December 2020

Full year January – December 2020· Net sales amounted to KSEK 0 (0) · Operating loss amounted to SEK -48 million (-165) · Earnings per share amounted to SEK -0.31 (-1.76) Quarter October – December 2020 · Net sales amounted to KSEK 0 (0) · Operating loss amounted to SEK -12 million (-17). · Earnings per share amounted to SEK -0.08 (-0.15) Significant events October – December · Directed share issues in myFC bring in SEK 36 million and a Share Subscription Agreement signed with Global Emerging Markets adds an additional SEK 150 million of available funding ·

Interim report October - December 2020

Quant releases the interim report for October - December 2020.October-December · Net sales for the period decreased by 13.7% to EUR 43.4 (50.3) million. Organically, net sales decreased by 7.3% · During the quarter, the contract portfolio decreased as nine contracts were lost, two contracts were won, and one contract was renewed. Portfolio run rate annualized net sales at the end of the quarter was EUR 140.5 million, compared to EUR 165.4 million during the third quarter of 2020 · Operating loss amounted to EUR -1.3 million, compared to a profit of EUR 0.8 million prior year ·

Nordic Iron Ore AB secures financing of SEK 20.9 million

Nordic Iron Ore AB ("Nordic Iron Ore" or "the Company") has decided to raise loans totaling SEK 20.9 million. The motive is to provide working capital to evaluate alternative financing options and continued design work.As previously announced, Nordic Iron Ore received a very positive result in November 2020 from the optimization study for the project in Blötberget. Based on this study, discussions have been initiated regarding the project's long-term financing. - The iron ore market is very strong, not least in terms of demand for the high-quality product that we will produce. These are

XNK Therapeutics partners with Karolinska Institutet on Phase II study in patients with multiple myeloma with support from Sanofi

XNK Therapeutics AB (“XNK”) today announced that it is entering into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s leading drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa (isatuximab). XNK and Sanofi are both collaborative partners within NextGenNK Competence Center coordinated by Karolinska Institutet.The investigator-initiated Phase II study is made possible by the three parties’ contributions to the trial. XNK will provide its novel autologous NK cell-based product to the study set to take place at the Karolinska University

Kamux Corporation’s Financial Statements Bulletin for January 1 - December 31, 2020

Kamux Corporation Financial Statements Bulletin February 26, 2021 at 09:00 Kamux Corporation’s Financial Statements Bulletin for January 1 - December 31, 2020 Kamux Saw Strong and Very Profitable Growth - Revenue Growth +13.3% and Adjusted Operating Profit +38.8% The figures in parentheses refer to the comparison period, i.e. the same period in the previous year, unless stated otherwise. October-December in brief- Revenue increased by 13.3%, totaling EUR 198.8 million (175.4) - Gross profit increased by 18.7% to EUR 23.8 million (20.0), or 12.0% (11.4) of revenue -

ICA Gruppen publishes annual report 2020

ICA Gruppen’s annual report for 2020 is now available at www.icagruppen.seThe annual report, which also includes ICA Gruppen’s sustainability report, is available as a downloadable PDF document. To read or download the annual report in English, go to: www.icagruppen.se/en/annual-report-2020 To read or download the annual report in Swedish, go to: www.icagruppen.se/arsredovisning-2020 For environmental and cost reasons, and because ICA Gruppen is increasingly switching to digital communication, from the 2018 Annual Report onwards ICA Gruppen has decided to no longer provide a

Otello trading update

AdColony update AdColony continued the strong growth in 4Q20 delivering revenue growth of 34% vs 4Q19. This is substantially above guidance of 10-15% revenue growth provided at our 3Q20 presentation and above the 30% updated guidance we provided in our profit warning on 21. December 2020. 4Q20 Our Brand business continues to outgrow the market and posted 43% YoY growth in 4Q20 vs 4Q19, driven in particular by our Programmatic business. In addition, our Performance business delivered in 4Q20 the first quarter with quarter with YoY growth since 2016. Despite the strong revenue growth,

Notice to the annual general meeting of UPM-Kymmene Corporation

UPM-Kymmene Corporation       Stock Exchange Release (Notice to General Meeting)     26 February 2021 at 09:00 EET Notice to the annual general meeting of UPM-Kymmene Corporation Notice is given to the shareholders of UPM-Kymmene Corporation of the Annual General Meeting to be held on Tuesday, 30 March 2021 starting at 14.00 (EEST) in UPM-Kymmene Corporation’s headquarters at Biofore House, Alvar Aallon katu 1, Helsinki, Finland. The Company’s shareholders can participate and exercise their shareholder rights in the Annual General Meeting only by voting in advance and by submitting

Kamux Corporation’s Share-Based Long-Term Incentive Plan for 2021―2023

Kamux Corporation    Stock Exchange Release    26 February 2021 at 8:50 (EET) Kamux Corporation’s Share-Based Long-Term Incentive Plan for 2021―2023 The Board of Directors of Kamux Corporation have decided to approve the new long-term incentive plan for the Group’s key persons for 2021-2023 (the “Plan”). The aim of the Plan is to encourage and strengthen the commitment of the Group's key persons to implement a long-term strategy and increase shareholder return, as well as to align the objectives of the company's shareholders and key persons in order to increase the company's value.

Tecnotree Board of Directors approves the Long Term Incentive (LTI) plan for 2021-2024 and the issuance of shares to Tecnotree

Tecnotree Corporation Stock Exchange release 26 February 2021 at 08:45 (CET +1)After succesfull implementation of LTI 2019-2022, Tecnotree announced today that its Board of Directors has approved the company's employee incentive program for 2021-2024 (the "LTI-2 Plan") designed to align the participants' focus with Tecnotree’s growth strategy and long-term success. The LTI-2 Plan includes the following instrument: · Restricted Share Units (RSUs) giving a contractual right to receive shares over the next 3 year period as per an equated semi-annual vesting schedule. LTI-2 Plan

Borr Drilling Limited Announces Preliminary Results for the Fourth Quarter and Full Year of 2020

Hamilton, Bermuda, February 26, 2021: Borr Drilling Limited (“Borr”, “Borr Drilling” or the “Company”) announces unaudited results for the three and twelve months ended December 31, 2020. Highlights in the Fourth Quarter of 2020 •    Total operating revenues of $60.2 million, net loss of $46.7 million and Adjusted EBITDA  of $6.6 million for the fourth quarter of 2020. •    On October 5, 2020, equity offering raised total proceeds of $27.5 million. A subsequent offering closed on November 30, 2020, raising an additional $5.3 million. •    The Company entered into agreements to

Arctic Paper S.A. Q4, 2020 - preliminary results*: Good results and strengthened position in turbulent times

• Q4 sales revenue amounted to PLN 714,7mn (EUR[1] 160,8mn).• EBITDA Q4 was PLN 25,1mn (EUR[1] 5,6mn) and the EBITDA marginal 3,5 percent• FY 2020 sales revenue amounted to PLN 2847,5mn (EUR[1] 640,6mn).• EBITDA FY 2020 was PLN 271,4mn (EUR[1] 61,6mn) and the EBITDA margin 9,5 percent• Paper & Pulp – a resilient combination providing a balanced development over time.• Strong consolidated result: net debt/EBITDA ratio reduced to 0,49 (0,57).• Strengthened market position and recovery in paper production and sales during Q4.• Increased investments in sustainable energy: hydro

Kamux Corporation publishes its strategy for the period 2021―2023

Kamux Corporation      Insider information    26 February 2021 at 8:40 Kamux Corporation publishes its strategy for the period 2021―2023 During the strategy period 2021―2023, Kamux aims to increase revenue by over 20% annually, to increase adjusted operating profit annually, and to reach an adjusted operating profit margin of at least 3.5% and a return on equity (ROE) of over 25%. Additionally, the company’s target is to distribute dividends of at least 25% of net profits. “Thanks to Kamux’s effective business model, the company has grown profitably and expanded internationally

ABAX Q4 Completed Revenue Results – Revenue Growth of 29%

26.02.2021, Larvik, Norway | ABAX Group announces its Q4 results and is available on their website at: https://www.abax.com/uk/investor-relations/financial-reportsQ4 highlights: ABAX reports a strong Revenue Growth in Q4 of 29% and Organic Growth of 4%. During Q4 2020 ABAX completed a major acquisition in Sweden which added over 87.000 subscriptions to ABAX. In addition to the acquisition ABAX successfully launched their first fully integrated product during this period.   For more information please contact: Morten Strand, CEO, ABAXEmail: morten.strand@abax.noPhone: +47

Read original

Raytelligence – Year End Report 2020

October 1 – December 31, 2020 •   Net sales SEK 0 •   Operation profit SEK -2,028,758 •   Profit after financial items SEK -2,028,758 •   Earnings per share SEK -0,09 January 1 – December 31, 2020 •   Net sales SEK 342,000 •   Operation profit SEK -6,450,727 •   Profit after financial items SEK -6,453,650 •   Earnings per share SEK -0,29  •   Cash and cash equivalents 2020-12-31 SEK 20,119,163 Number of shares Per 2020-12-31, 21 907 369 shares Proposed dividend        The Board proposes that no dividend be paid for the 2020 financial year.

Kongsberg Automotive reports Q4 2020 results

Kongsberg Automotive ASA will host an earnings conference call at 09:00 CET, today.  KEY TOPICS · COVID-19: 2020 was a year dominated by the effects of the coronavirus disease (COVID-19). The virus and a weak start to the year 2020 have impacted the automotive industry heavily. However, in Q4 we have observed a strong rebound in sales and new business wins. The Q4 production levels represent a stronger recovery from the coronavirus impact than expected. · Revenues: Q4 2020 Kongsberg Automotive revenues amounted to MEUR 299, MEUR 18 (6%) above Q4 2019, including negative

Nanoform 1-12/2020 report and new company near-term target introduced

Company Announcement Nanoform Finland Plc February 26, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform 1-12/2020 report and new company near-term target introduced First GMP manufacturing campaign and first dosing in humans successfully completed, positive interim results from first clinical study announced, all near-term business targets set out in IPO achieved, ten new Small Molecule PoC projects started, four more non-GMP lines commissioned, first Biologics PoC project commenced and a new near-term business target introduced: “At least 3 new non-GMP lines

Nanoform sets new near-term business target for 2021 and 2022

Insider information Nanoform Finland Plc February 26, 2021 08:05 a.m. Finnish time / 07:05 a.m. Swedish time Nanoform sets new near-term business target for 2021 and 2022 Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced a new near-term business target. In 2021 and 2022 the company hereby targets “At least 3 new non-GMP lines in 2021 and 2 new GMP lines in 2022”. Nanoform also re-iterated it’s other near-term target, announced January 4 (2021), of “at least a dozen new non-GMP customer projects and

There are no items matching the current filter
There are no more items matching the current filter
Back to top